Astellas Pharma Global Development, Inc.

This early study tests a new drug, ASP2998, that attaches to a protein called TROP2 found on many solid tumors to attack cancer cells. It is given alone or with standard treatments like pembrolizumab or carboplatin. The study includes adults with advanced bladder, lung, stomach, …

This study tests whether adding the experimental drug setidegrasib to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS G12D mutation) live longer. About 614 adults whose cancer has spread and cannot be removed by surgery will receive eit…

This early-stage study tests a new drug called ASP1002 in adults with advanced solid tumors that have high levels of a protein called claudin 4. The main goals are to check the drug's safety, find a safe dose, and see how well people tolerate it. Participants receive the drug thr…

This study tests a combination of two drugs, enfortumab vedotin and pembrolizumab, for people with muscle-invasive bladder cancer. The goal is to see if this treatment can control the cancer and allow patients to keep their bladder instead of having it surgically removed. The stu…

This study tests roxadustat, a pill taken three times a week, to treat anemia in children and teenagers with chronic kidney disease. Anemia means low red blood cells, which can cause tiredness. Current treatment requires injections, but this pill might be easier. About 100 kids w…

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or other solid tumors that have a specific protein (CLDN18.2). The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in…

This study tests whether adding zolbetuximab to standard immunotherapy (pembrolizumab) and chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. About 500 adults whose tumors have specific markers (CLDN18.2-positive, PD-L1-positive, HER2…

This study tests the safety of enfortumab vedotin in 100 Indian adults with advanced or spreading bladder cancer (urothelial carcinoma) that has worsened after prior treatment. Participants receive the drug through an IV infusion every 4 weeks. The main goal is to monitor side ef…

This early study tests a new drug, ASP2138, given as a shot two weeks before surgery for people with a type of pancreatic cancer that has a specific protein (CLDN18.2). After surgery, patients receive standard chemotherapy for up to six months. The main goal is to check safety an…

This study looks at the long-term safety of the drug enzalutamide in people with prostate cancer who are already benefiting from it in an earlier study. About 900 participants will continue their treatment and be monitored for side effects. The goal is to gather more safety infor…

This study tests a new injectable drug, ASP5541, for men with advanced prostate cancer that has spread. The drug is a different form of the standard treatment abiraterone, given as a shot every 12 weeks instead of daily pills. The study will compare how well the injection works a…

This program offers early access to zolbetuximab, a targeted therapy, for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN18.2) and is not HER2-positive. Participants receive zolbetuximab alongside standard chemotherapy to help co…

This early-stage study tests a new drug called ASP5541 in about 12 Chinese men whose prostate cancer has spread. The drug is given as a shot in the hip, along with standard treatments (prednisone and hormone therapy). The main goals are to check the drug's safety and how it moves…

This early-stage study tests gilteritinib, a drug already used for a type of leukemia, in people with a specific kind of lung cancer (ALK-positive NSCLC) that has stopped responding to standard treatments. About 40 adults will take the drug daily to see if it is safe and tolerabl…

This study tests whether two drugs, enfortumab vedotin and pembrolizumab, can control muscle-invasive bladder cancer without needing surgery to remove the bladder. About 390 adults whose cancer hasn't spread outside the bladder will get either the drug combo or standard chemoradi…

This study tests a new medicine called PRL-02 depot, given as a shot into the muscle every 12 weeks, to lower testosterone in men with advanced prostate cancer. The goal is to find a safe dose and see if it works alone or with another drug, enzalutamide. About 174 men whose cance…

This early-phase study tests a new drug, ASP2138, that helps the immune system find and attack cancer cells that have a specific marker called CLDN18.2. The study includes adults with advanced stomach, gastroesophageal junction, or pancreatic cancer that cannot be removed by surg…

This study follows 1,000 people with geographic atrophy (an advanced form of age-related macular degeneration) who are already being treated with the drug Izervay. Researchers will collect information from medical records and patient surveys over up to 5 years to see how the drug…

This study tests how three common drugs (fluconazole, itraconazole, and carbamazepine) change the way the body processes a new experimental cancer drug called ASP3082. About 54 healthy adults will receive ASP3082 alone and then with each of the other drugs. The goal is to measure…

This study follows children (over 6) and adults with Stargardt disease or similar inherited eye conditions to see how their vision changes over 2 years. Participants get standard eye tests every 6 months, but no new treatment is given. The goal is to better understand how these d…